BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Reneviaa in Europe

BioTime, Inc. today reported that it has received authorization to begin its pivotal human clinical trial of Reneviaa in Europe. In the trial, Renevia will be used in combination with the patient's own fat-derived cells and injected into portions of the patient's face where there has been a loss of fat from under the skin .

http://ift.tt/1upJfQQ